Heliox for prevention of morbidity and mortality in ventilated newborn infants
Editorial Group: Cochrane Neonatal Group
Published Online: 16 JUL 2008
Assessed as up-to-date: 7 MAY 2008
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Molloy EJ, McCallion N, O'Donnell CPF, Davis PG. Heliox for prevention of morbidity and mortality in ventilated newborn infants (Protocol). Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No.: CD007304. DOI: 10.1002/14651858.CD007304.
- Publication Status: New
- Published Online: 16 JUL 2008
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effect of Heliox on rates of mortality, neurodevelopmental impairment and bronchopulmonary dysplasia in ventilated infants and to evaluate the safety profile of heliox in this population.
- Preterm infants
- Infants wtih evolving or established chronic lung disease